skip to main content

Breast Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardBreast CancerBreast CancerSCE Medical Oncology

A postmenopausal patient remains disease-free after five years of tamoxifen for node-positive grade 3 ER-positive/HER2-negative early breast cancer. Bone health is acceptable and she wants maximal evidence-based endocrine risk reduction. Which strategy is most appropriate to discuss?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Switch to an aromatase inhibitor as extended adjuvant endocrine therapy

Higher-risk ER-positive disease retains late-recurrence risk. In a postmenopausal patient after tamoxifen, extended therapy with an aromatase inhibitor is appropriate to discuss, balancing bone and other toxicity. Fulvestrant and alpelisib are not adjuvant substitutes, concurrent indefinite tamoxifen plus AI is not the standard strategy, and automatic cessation ignores risk.

Reference: NICE NG101: early and locally advanced breast cancer. https://www.nice.org.uk/guidance/ng101/chapter/Recommendations